What are the best indicators to assess malnutrition in idiopathic pulmonary fibrosis patients? A cross-sectional study in a referral center by Jouneau, Stéphane et al.
HAL Id: hal-02088078
https://hal-univ-rennes1.archives-ouvertes.fr/hal-02088078
Submitted on 12 Apr 2019
HAL is a multi-disciplinary open access
archive for the deposit and dissemination of sci-
entific research documents, whether they are pub-
lished or not. The documents may come from
teaching and research institutions in France or
abroad, or from public or private research centers.
L’archive ouverte pluridisciplinaire HAL, est
destinée au dépôt et à la diffusion de documents
scientifiques de niveau recherche, publiés ou non,
émanant des établissements d’enseignement et de
recherche français ou étrangers, des laboratoires
publics ou privés.
What are the best indicators to assess malnutrition in
idiopathic pulmonary fibrosis patients? A cross-sectional
study in a referral center
Stéphane Jouneau, Mallorie Kerjouan, Chloé Rousseau, Mathieu Lederlin,
Francisco Llamas-Guttierez, Bertrand de Latour, Stéphanie Guillot, Laurent
Vernhet, Benoit Desrues, Ronan Thibault
To cite this version:
Stéphane Jouneau, Mallorie Kerjouan, Chloé Rousseau, Mathieu Lederlin, Francisco Llamas-
Guttierez, et al.. What are the best indicators to assess malnutrition in idiopathic pulmonary fi-
brosis patients? A cross-sectional study in a referral center. Nutrition, Elsevier, 2019, 62, pp.115-121.
￿10.1016/j.nut.2018.12.008￿. ￿hal-02088078￿
ACCEPTED MANUSCRIPT
AC
CE
PT
ED
 M
AN
US
CR
IP
T
1 
 
Highlights 
 Malnutrition is very frequent in idiopathic pulmonary fibrosis (IPF) patients. 
 Low fat-free mass index (FFMI) assessed by bioimpedance analysis (BIA) is reported in 
28% of patients. 
 Body mass index (BMI) and mid-arm circumference (MAC) are independently 
associated with low FFMI. 
 A two-step nutritional assessment based on BMI, MAC and BIA should be routinely 
performed in IPF patients. 
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ABSTRACT 
Background & aims: Little is known about the indicators to assess malnutrition in patients 
with idiopathic pulmonary fibrosis (IPF). This study aimed to determine: i) the prevalence of 
malnutrition in IPF patients, ii) the nutritional indicators predictive of low fat-free mass 
(FFM) as measured by bioimpedance analysis; iii) the IPF patients’ characteristics associated 
with low FFM. Methods: The IPF patients were consecutively recruited in a referral centre for 
Rare Pulmonary Diseases. Malnutrition was defined as a fat-free mass index (FFMI) = FFM 
(kg)/(height (m)
2
) <17 (men) or <15 (women). Nutritional assessment included body mass 
index (BMI), mid-arm circumference (MAC), triceps skinfold thickness, analogue food intake 
scale, and serum albumin and transthyretin. Primary endpoint: FFMI. Statistics: area under 
the receiver operating characteristic curve (AUC) assessed low FFMI prediction from 
nutritional indicators. Multivariable logistic regression: variables associated with low FFMI. 
Results: Eighty-one patients were consecutively recruited. Low FFMI prevalence was 28% 
(23/81). BMI AUC was 0.91 [95% CI, 0.84‒0.97] and MAC AUC was 0.85 [0.76‒0.94]. 
Multivariable analysis associated BMI (Odds ratio (OR) 0.26 [95% confidence interval (CI) 
0.12 – 0.54], P=0.0003), male gender (OR 0.02 [0.00 – 0.33], P=0.005), and smoking (OR 
0.10 [0.01 – 0.75], P=0.024) with a lower risk of malnutrition. Conclusion: Malnutrition 
occurred in nearly one third of IPF patients. Malnutrition screening should become 
systematic, based on BMI and MAC that are good clinical indicators of low FFMI. We 
propose a practical approach to screen malnutrition in IPF patients. 
 
Keywords: malnutrition; lean body mass; food intake; bioelectrical impedance analysis; 
interstitial lung disease. 
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INTRODUCTION 
Idiopathic pulmonary fibrosis (IPF) is a chronic, progressive, and irreversible lung disease 
with a poor prognosis and a median survival after diagnosis of 3–5 years (1-3). IPF is the first 
aetiology of chronic idiopathic interstitial pneumonia in adults, and is associated with several 
comorbidities (4). Malnutrition, defined as low body mass index (BMI) or low fat-free mass 
(FFM) (5-8), is an independent predictor of mortality in patients with chronic obstructive 
pulmonary disease (COPD), another chronic, progressive, and irreversible lung disease. FFM 
is the nutritional indicator the best correlated with COPD patient’s survival (7). Although 
BMI is widely used to assess nutritional status, it is an insensitive detector of impaired FFM 
in COPD patients (7, 9). Bioelectrical impedance analysis (BIA) is the simplest and most 
accurate method for assessing body composition in clinical practice (9, 11-13). Pulmonary 
rehabilitation improves the FFM of COPD patients (14). The prognosis for IPF patients with a 
low BMI (15) or low BMI plus respiratory parameters (16), and low FFM (17) is poor. 
However, to our knowledge, little is known regarding the nutritional assessment of IPF 
patients. The IPF management guidelines do not cover nutritional status assessment (2, 18) or 
the nutritional criteria for assessing disease stage and prognosis (2). Therefore it is needed to 
determine the best indicators for assessing IPF patients’ nutritional status. In this cross-
sectional study in consecutive IPF patients, we aim to assess the prevalence of malnutrition; 
to identify the most reliable clinical and biochemical nutritional indicators (BMI, weight loss, 
low energy intake, mid-arm circumference, triceps skinfold, serum albumin and transthyretin) 
for predicting low FFM diagnosed by BIA; and, using multivariate analysis, to identify the 
demographic, respiratory, and nutritional variables associated with low FFM. Our results 
should provide practical advice for detecting early stage malnutrition in IPF patients, form the 
basis for future prospective randomized controlled trials on IPF patient nutrition, and, at best, 
should contribute to elaborate nutritional recommendations in future IPF guidelines. 
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PATIENTS AND METHODS 
Study design 
This single-centre cross-sectional study used prospective data collection. Patients were 
recruited from several general hospitals and private physicians, and assessed at Rennes 
University Hospital (CHU Rennes). 
 
Study population 
The patients were recruited between May and December 2016 at a French tertiary referral 
centre for IPF: the Competence Centre for Rare Pulmonary Diseases (‘Centre de 
Compétences Maladies Pulmonaires Rares’), Department of Respiratory Medicine, Rennes 
University Hospital (CHU Rennes), Rennes, France. We collected data from all consecutive 
patients with stable IPF, as defined in multidisciplinary discussions (2, 18) who had been 
without infection or exacerbation in the eight weeks preceding their first appointment. This 
study was approved by the hospital Ethic Committee (n°17.53). 
 
Clinical and biological assessment of nutritional status 
The nutritional status of all patients was assessed by a single pulmonologist physician (SJ). 
This initial medical consultation included assessment of weight, height, mid-arm 
circumference (MAC; tape measure) and triceps skinfold thickness (TSF; adipometer). Body 
mass index was calculated as: weight (kg) / (height (m)
2
. Mid-arm muscular circumference 
(MAMC) (cm) was calculated as: MAC (cm)-( x TSF (cm)). Food intake was systematically 
assessed with the ten-point analogue visual scale of the Simplified Evaluation of Food 
Intake® (SEFI®), as previously described (19). Patients moved the cursor on the scale to 
answer the question: ‘How much do you presently eat, ranging from ‘nothing at all’ (far left 
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of the scale) to ‘as usual’ (far right side of the scale)?’ Results were expressed as a number 
between 0 and 10. Nutritional biological parameters of all patients (serum albumin and 
transthyretin) and CRP were also measured. 
 
Bioelectrical impedance analysis (BIA) 
Body composition, including FFM, fat mass, total body water, extracellular and intracellular 
water, and 50-kHz phase angle, were measured with a multifrequency bioimpedance 
generator/analyser (Quadscan 4000, Bodystat Ltd, Isle of Man, UK). Briefly, patients lay 
supine with the palms of their hands facing inwards and  areas of skin on the backs of their 
left hand, left wrist, left foot, and left ankle were cleaned with 70 % ethanol and four adhesive 
electrodes (3M Red Dot T; 3M Health Care, Borken, Germany) were placed on them. An 0.8 
mA electrical current at frequencies of 5, 50, 100, and 200 kHz produced by the 
bioimpedance generator/analyser was used to measure whole-body resistance (R) and 
reactance (Xc) (11). Phase angles were calculated from: phase angle (°) = arctan(Xc/R) × 
(180/π). Fat-free mass index (FFMI) was calculated as: fat-free mass (kg) / (height (m)
2
. 
FFMI was considered to be low if it was below 17 in men or below 15 in women, as in COPD 
patients (8, 20). The body fat mass index (BFMI) was calculated as: fat mass (kg)/(height 
(m)
2
. 
 
Respiratory and other data collection 
Demographic (gender, age) and clinical data (disease duration, comorbidities, current drug 
use, tobacco use, performance of surgical lung biopsy), pulmonary function test (PFT) and 
six-minute walk test (6MWT) parameters, were collected from the hospital electronic medical 
database. Dyspnoea was assessed using the New York Health Association (NYHA) scale. 
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PFT and 6MWT were performed according to international guidelines (21, 22). The gender, 
age and physiology (GAP) index was calculated as proposed by Ley et al. (23). 
 
Statistical analysis 
Descriptive statistics are expressed as means ± standard deviations (SD) or medians and 
interquartile ranges for continuous data, according to their distribution, and as the number of 
patients (with the percentage in parenthesis, followed immediately by the counts for the 
numerator/denominator) for categorical data. ROC curves were used to analyse the 
association of each nutritional variable with low FFM and to find the best cut-off associated 
with low FFM by the Youden method. ROC curves were analysed with their AUCs and 95 % 
confidence intervals (CIs). The discriminative power of the AUC was defined as: 0.90 ≤ AUC 
≤ 1.0, excellent; 0.80 ≤ AUC < 0.90, good; 0.70 ≤ AUC < 0.80, fair; 0.60<AUC< 0.70, poor; 
0.50 ≤ AUC < 0.60, failure (24). We analysed the FFM with χ2 tests (or Fisher’s exact test 
when appropriate) for categorical data, and Student’s t-test (or Mann–Whitney–Wilcoxon / 
Kruskall Wallis test when appropriate) for continuous data. Multivariable logistic regression 
analysis adjusted for factors with P values of <0.2 in univariate analysis was performed with 
backward stepwise elimination of all variables that did not contribute (P value ≥0.05). The 
adjusted Odds ratio of continuous variables was expressed for 1-point increases. Sensitivity, 
specificity, positive predictive value and negative predictive value, and their 95 % CIs were 
calculated according to the Youden method. Statistics were computed with SAS software 
V9.4 (SAS Institute Inc., Cary, NC, USA), and two-tailed P values of <0.05 were considered 
statistically significant. 
 
RESULTS 
Patients’ clinical and demographics characteristics 
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The study included 81 patients (72 (88%) men) with IPF whose clinical characteristics are 
shown in Table 1. The mean age was 74.4 ± 8.6 years. Of these, 41 were taking antifibrotic 
medication at inclusion: 18 (32%) patients with nintedanib (mean duration - 597 ± 635 days; 
range 54 - 1765 days) and 23 (28%) with pirfenidone (mean duration - 449 ± 267 days; range 
20 - 1049 days. The remaining 40 patients (49%) were either taking no antifibrotic medication 
because they were newly diagnosed (n=20 (25%)), did not tolerate or refuse antifibrotic 
medication, or their disease was too severe to be treated (i.e. FVC < 50% pred and/or TLCO < 
30% pred). 
 
Prevalence of malnutrition in IPF patients 
In the 81 IPF patients the prevalence of malnutrition based on BIA, i.e. low FFM, was 28% 
(23/81) (Table 2). This prevalence was lower using other definitions: 4% (3/81) based on 
BMI<21, 5% (4/81) based on MAC (<250 mm in women and <260 mm in men), and 9% 
(7/81) based on MMAC (<190 mm in women and <240 mm in men). 
 
Relationship between fat-free mass and clinical and biological nutrition assessment 
parameters 
Low FFMI was significantly associated with lower values for BMI, MAC, TSF, and hence 
MAMC (Table 2). The sensitivity, specificity, positive predictive value, and negative 
predictive value, defining the capacity of BMI<21 for predicting low FFMI were respectively: 
13%, 100%, 100%, and 74%. Lower FFMI was associated with a lower 50 kHz phase angle 
(25) and a higher percentage of fat mass. Patients with low FFMIs were older, more 
frequently women, non-smokers, had a lower TLCO, and were less likely to be diagnosed 
using surgical lung biopsy (Table 1). Symptoms (dyspnoea, cough, digital clubbing) or IPF 
drug therapy were not associated with a low FFMI. Neither were changes in serum albumin 
ACCEPTED MANUSCRIPT
AC
CE
PT
ED
 M
AN
US
CR
IP
T
10 
 
and serum transthyretin. The variables significantly associated with a reduced risk of low 
FFMI in multivariable logistic regression were BMI, male gender, and smoking. The capacity 
of MAC to predict low FFMI was assessed by replacing BMI with MAC in the multivariable 
model. Two variables were then significantly associated with less risk of low FFMI: MAC 
(OR 0.48 [0.32 – 0.70], P=0.0002), and male gender (OR 0.06 [0.01 – 0.46], P=0.0062). We 
further tested the predictive values of BMI and MAC for low FFMI. The area under the 
receiver operating characteristic curve assessing low fat-free mass index (FFMI) prediction by 
BMI was: 0.91 [95% CI, 0.84‒0.97] (Figure 1), and the area for MAC was 0.85 [0.76‒0.94] 
(Figure 2), indicating their excellent (BMI) and good (MAC) discriminative powers for low 
FFMI. An IPF patient with a BMI≥25 and a MAC ≥30 cm was 100% likely to have a normal 
FFMI (Table 4). MAMC (AUC = 0.79, 95% CI, 0.69‒0.90) and phase angle (AUC = 0.72, 
0.61‒0.84) were both fair predictors of FFMI loss. 
 
Relationship between food intake, nutritional parameters, and IPF drug use 
As reduced food intake is a well-known indicator of malnutrition, we assessed the factors 
associated with decreased food intake as indicated by the SEFI®. Patients with an SEFI® 
analogue score of <7 had a lower TLCO (34.4±13.6%) than those with a SEFI® score ≥7 
(46.0±14.9%, P=0.0028), suggesting a link between decreased food intake and disease 
severity. Patients with a SEFI® analogue score <7 had lower values for MAC (28.3±2.7 vs. 
29.9±2.5 cm, P=0.01), MAMC (26.3 ±2.6 vs. 27.6 ±2.3 cm, P=0.025), and phase angle 
(4.6±1.0 vs. 5.2±0.9 degrees, P=0.012) than those with a SEFI® score ≥7, suggesting a more 
impaired nutritional status when energy intake is decreased. However, FFMI (17.7 ± 3.3 vs. 
18.2 ± 2.3) and the percentage of patients with low FFMI (8/27 (30%) vs. 15/54 (28 %)) were 
not statistically different in patients with SEFI® score <7 or ≥7. Patients on pirfenidone (6.9 ± 
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2.4) tended to report a lower SEFI® analogue score than patients on nintedanib (7.4 ± 2.7) or 
who were untreated (8.2 ± 2.3) (P=0.0516). 
 
DISCUSSION 
In this cross-sectional study, nearly one third (28%) of the IPF patients were malnourished, as 
defined by a low FFMI based on BIA. Decreased BMI and MAC, female gender, and never-
smoking were strong predictors of low FFM. As a low FFMI has been suggested to affect IPF 
prognosis (17), a systematic nutritional assessment should be routinely recommended for IPF 
patients. 
To our knowledge, this is the first study to determine, in IPF patients, if usual nutritional 
indicators could predict low FFMI measured by BIA. Measuring BMI with a cut-off of <21, 
as recommended for COPD patients (8, 14, 20), is an insensitive method for diagnosing 
malnutrition, and largely underestimates the problem. It indicated that only 4% were 
malnourished, while a low FFMI derived from BIA diagnoses 28%, indicating that 87% of 
patients with low FFMI having BMI ≥21 were false negatives. This poor sensitivity of BMI 
<21 has been reported for COPD patients, for whom BIA is the most sensitive method for 
diagnosing malnutrition (9, 20). However, when choosing the right cut-offs, BMI is excellent, 
and MAC good, at predicting low FFMI. The most discriminative cut-off for BMI was 25.4 
with excellent sensitivity and negative predictive value, but the specificity and positive 
predictive values were poor because it produced many false positives. MAC<295 mm and a 
combination of BMI and MAC gave similar predictive profiles. We believe that these results 
will prove useful in daily clinical practice. 
Our data indicate that malnutrition is common in IPF patients: nearly one third of them were 
malnourished. This is important because some studies  on IPF patients suggested that a low 
BMI, alone (15) or combined with respiratory parameters (16), and low FFM derived from 
ACCEPTED MANUSCRIPT
AC
CE
PT
ED
 M
AN
US
CR
IP
T
12 
 
BIA (17), are associated with a poor prognosis. But none of them assessed the prevalence of 
malnutrition, even based on BMI<21 or low FFMI. Alakhras et al. carried out a retrospective 
analysis of a US cohort of IPF patients and reported the relationship between BMI and 
mortality (15). Patients with a BMI ≥ 30 had a better survival rate than those with BMIs < 25 
and 25-30. A retrospective Japanese study on 65 patients with IPF found that a one-point 
increase in BMI over 12 months was associated with 10% fewer deaths (16). A recent study 
of 44 Japanese IPF patients (17) evaluated the prognosis value of FFMI. The FFMI (hazard 
ratio (HR): 0.64, 95% CI: 0.43–0.94, P=0.02) and percentage predicted FVC (HR: 0.96, 95% 
CI: 0.93–0.99, P=0.008) were significant predictors of survival. Nutritional status was not 
correlated with respiratory parameters such as percentage predicted FVC, percentage 
predicted TLCO, or 6MWT (15, 17). We found that the percentage predicted TLCO was 
significantly lower in IPF patients with a low FFMI. It is now clearly needed to determine 
whether the prognostic prediction could be improved by combining nutritional and respiratory 
parameters. A low serum albumin was independently associated with increased mortality in 
1269 patients with idiopathic interstitial pneumonia on the waiting list for lung transplantation 
in the US (26). The clinical profiles of the patients included in these studies differed from 
those of our patients. In Kishaba et al. study, most of the patients (74%) were treated with 
prednisone alone or prednisone plus ciclosporin (16). In Nishiyama et al. study, the patients 
had lower BMIs, only one had been diagnosed as IPF with a surgical lung biopsy, a lower 
TLCO, but young patients and those treated with anti-fibrotics ( pirfenidone or nintedanib), or 
on long-term oxygen therapy were excluded (17). All those diagnosed with idiopathic 
interstitial pneumonia before the 2011 guidelines for IPF were published (2) had more severe 
disease and were eligible to lung transplant (26). Our cross-sectional study did not assess the 
relationship between FFMI and prognosis. A longitudinal study is needed to assess the impact 
of FFMI on survival according to disease severity, and therapy (oxygen supplements or anti-
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fibrotic medications), in normal clinical practice. Nevertheless, the link between the loss of 
FFM and prognosis and illness severity emphasises the value of using BIA for managing 
patients with chronic diseases like IPF. 
As expected, those patients with decreased FFMI were relatively old. The fact that patients 
diagnosed by surgical lung biopsy were less likely to have a low FFMI could be explained by 
their early diagnosis as they did not have to wait for there to be honeycombing on the chest 
CT-scan (27, 28), indicating more severe disease at the time of nutritional screening. We have 
no clear explanation why women and non-smokers are so likely to lose FFMI. The 
mechanisms underlying malnutrition in IPF patients remain unclear. As reported in COPD 
patients (29, 30), anorexia, insulin resistance, inflammation, and hypogonadism could all be 
involved. However, we found no link between food intake or C-reactive protein (CRP) 
concentration and FFMI. Nevertheless, the mean CRP concentration in our IPF patients (8.2 ± 
12.1 mg/L) was higher than those of COPD patients (3-4 mg/L), who are known to suffer 
from systemic inflammation (31, 32). 
We focussed specifically on antifibrotic therapy, but found no difference in the nutritional 
status of untreated patients and those treated with pirfenidone or nintedanib. However, 
patients on pirfenidone reported a slight decrease in food intake; this needs to be confirmed. 
BIA was chosen as the reference method for assessing FFM because it is easy to use for 
measuring body composition at the bedside or in outpatients (11-13), and has been well 
validated as an accurate measure of FFM and prognosis assessment in COPD patients (14). 
Our experience in this study confirmed the ease-of-use of BIA; all the measurements on all 
patients were obtained by a single physician (SJ) who had never used BIA before. 
Finally, this study has some limitations. Weight loss was not taken into account as a 
nutritional parameter, because many data were missing. They were all based on patients’ 
recall and so could be not considered as precise objective data. A longitudinal study is needed 
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to assess the predictive value of weight loss for assessing FFMI loss and disease prognosis. 
We used the FFMI cut-off values recommended for COPD patients. Nishiyama et al. used the 
median of FFMI to split their 44 IPF patients (17). The cut-off was 16.6 kg/m² for both 
genders, which is quite similar to the COPD cut-offs we used: women <15 and men <17. 
However, more studies are needed to determine the optimal cut-off for defining malnutrition 
in IPF patients. 
We conclude that malnutrition (i.e. low FFMI measured by BIA) is highly prevalent (nearly 
one third) in IPF patients. Therefore, malnutrition screening should become systematic, based 
on BMI and MAC that are good clinical indicators of low FFMI. Based on these indicators 
sensitivity, specificity, positive predictive value, and negative predictive value (Figures 1 and 
2, and Table 4), we propose a two-step assessment for malnutrition in IPF patients: 1) first 
step: measure BMI and MAC; if BMI ≥ 25 and MAC ≥ 300 mm, patient is likely not 
malnourished; if BMI<21 or MAC <295 mm, the patient is likely malnourished: dietician 
intervention is needed. 2) For all other situations, go to the second step: FFMI measurement 
by BIA: malnutrition if FFMI <15 (women) or <17 (men). Future studies should assess 
whether nutritional intervention targeted to FFM, e.g. pulmonary rehabilitation, could change 
IPF patient outcome. 
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Table 1- Clinical and demographic characteristics of patients with idiopathic pulmonary fibrosis (IPF). 1 
    
Variable 
All patients 
(n=81) 
Low FFMI 
(n=23) 
Normal FFMI 
(n=58) 
Odds ratio [95% 
confidence interval] P value 
      
Age (years) 74.4 ± 8.6 77.5 ± 6.8 73.1 ± 9.0 1.07 [1.00 – 1.15] 0.0375 
 (42.0; 68.0; 76.0; 80.0; 
89.0) 
(59.0; 74.0; 78.0; 83.0; 
86.0) 
(42.0; 68.0; 75.0; 
79.0; 89.0) 
  
Gender      
Female 10 (12.3%) 8 (34.8%) 2 (3.4%) Reference 0.0005 
Male 71 (87.7%) 15 (65.2%) 56 (96.6%) 0.07 [0.01 – 0.35]  
      
Smoking status      
Never 31 (38.3%) 13 (56.5%) 18 (31.0%) Reference 0.0333 
Yes 50 (61.7%) 10 (43.5%) 40 (69.0%) 0.35 [0.13 – 0.94]  
      
Cough      
No 25 (30.9%) 6 (26.1%) 19 (32.8%) Reference 0.5578 
Yes 56 (69.1%) 17 (73.9%) 39 (67.2%) 1.38 [0.47 – 4.07]  
      
Dyspnea 
(NYHA stages) 
     
I 7 (8.6%) 3 (13.0%) 4 (6.9%) Reference 0.5224 
II 16 (19.8%) 3 (13.0%) 13 (22.4%) 0.31 [0.04 – 2.17]  
III 43 (53.1%) 14 (60.9%) 29 (50.0%) 0.64 [0.13 – 3.28]  
IV 15 (18.5%) 3 (13.0%) 12 (20.7%) 0.33 [0.05 – 2.37]  
      
Digital clubbing      
No 53 (65.4%) 13 (56.5%) 40 (69.0%) Reference 0.2883 
Yes 28 (34.6%) 10 (43.5%) 18 (31.0%) 1.71 [0.63 – 4.62]  
ACCEPTED MANUSCRIPT
AC
CE
PT
ED
 M
AN
US
CR
IP
T 21 
 
    
Variable 
All patients 
(n=81) 
Low FFMI 
(n=23) 
Normal FFMI 
(n=58) 
Odds ratio [95% 
confidence interval] P value 
FVC (% pred) 81.4 ± 20.2 83.9 ± 21.1 80.4 ± 19.9 1.01 [0.98 – 1.03] 0.4886 
 (25.0; 68.5; 82.0; 96.0; 
128.0) 
(44.0; 68.0; 82.0; 100.0; 
124.0) 
(25.0; 69.0; 79.0; 
95.0; 128.0) 
  
      
TLCO (% pred) 42.3 ± 15.4 36.2 ± 13.8 44.6 ± 15.5 0.96 [0.92 – 1.00] 0.0404 
 (14.0; 33.0; 41.0; 54.0; 
72.0) 
(14.0; 26.0; 35.0; 39.0; 
69.0) 
(18.0; 35.0; 43.0; 
56.0; 72.0) 
  
      
GAP index 4.5 ± 1.5 4.7 ± 1.5 4.5 ± 1.5 1.10 [0.80 – 1.53] 0.4753 
 (2.0; 3.0; 4.0; 5.0; 8.0) (2.0; 3.0; 5.0; 6.0; 7.0) (2.0; 3.0; 4.0; 5.0; 
8.0) 
  
GAP class      
1 24 (29.6%) 7 (30.4%) 17 (29.3%) Reference 0.1756 
2 39 (48.1%) 8 (34.8%) 31 (53.4%) 0.63 [0.19 – 2.03]  
3 18 (22.2%) 8 (34.8%) 10 (17.2%) 1.94 [0.54 – 6.99]  
      
Time since 
diagnosis (days) 
626.4 ± 796.1 
(2.0 ; 119.0 ; 376.0 ; 712.0; 
3967.0) 
765.3 ± 1022.9 
(23.0 ; 191.0 ; 499.0 ; 
778.0 ; 3967.0) 
571.3 ± 689.0 
(2.0 ; 74.0 ; 354.0 ; 
703.0 ; 2945.0) 
1.00 [1.00 – 1.00] 0.2646 
Surgical lung 
biopsy: No 
 
61 (75.3%) 
 
21 (91.3%) 
 
40 (69.0%) 
 
Reference 
 
 
Yes 20 (24.7%) 2 (8.7%) 18 (31.0%) 0.21 [0.04 – 1.00] 0.0355 
      
Cancer      
No 73 (90.1%) 21 (91.3%) 52 (89.7%) Reference  
Yes 8 (9.9%) 2 (8.7%) 6 (10.3%) 0.83 [0.15 – 4.42] 1.0 
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Variable 
All patients 
(n=81) 
Low FFMI 
(n=23) 
Normal FFMI 
(n=58) 
Odds ratio [95% 
confidence interval] P value 
Cardiovascular 
comorbidities* 
     
No 28 (34.6%) 9 (39.1%) 19 (32.8%) 0.76 [0.28 – 2.06] 0.5866 
Yes 53 (65.4%) 14 (60.9%) 39 (67.2%) 
 
  
IPF drug      
Nintedanib 18 (22.2%) 3 (13.0%) 15 (25.9%) 0.47 [0.11 – 1.92] 0.4211 
Pirfenidone 23 (28.4%) 8 (34.8%) 15 (25.9%) 1.24 [0.42 – 3.71]  
None 40 (49.4%) 12 (52.2%) 28 (48.3%) Reference  
Qualitative variables: number (%). Quantitative variables: mean ± standard deviation (min; Q1; median ; Q3; max). FFMI, fat-free mass index; 2 
FVC, forced vital capacity; GAP index, the gender, age and physiology index; TLCO, carbon monoxide diffusion; % pred; percentage of 3 
predicted values. Missing data: FVC, n=1; TLCO, n=12. 4 
*Cardiovascular comorbidities included high blood pressure, history of stroke, myocardial infarction, atherosclerosis, etc… 5 
6 
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Table 2- Nutritional assessment of patients with idiopathic pulmonary fibrosis (IPF) (n=81). 7 
Variable 
All patients 
(n=81) 
Low FFMI 
(n=23) 
Normal FFMI 
(n=58) 
Odds ratio [95% 
confidence interval] P value 
Clinical parameters      
      
Weight (kg) 73.5 ± 11.4 60.7 ± 6.5 78.6 ± 8.6 0.69 [0.58 – 0.82] <0.0001 
 (41.6 ; 64.0 ; 73.0 
; 82.0 ; 95.0) 
(41.6 ; 57.4 ; 61.0 
; 65.0 ; 72.0) 
(61.0 ; 73.0 ; 77.0 ; 86.0 ; 
95.0) 
  
      
Body mass index 26.3 ± 3.3 23.2 ± 2.0 27.6 ± 2.9 0.42 [0.27 – 0.64] <0.0001 
 (17.3 ; 23.9 ; 26.0 
; 29.0 ; 35.3) 
(17.3 ; 21.9 ; 23.5 
; 24.5 ; 27.2) 
(22.2 ; 25.7 ; 27.5 ; 29.7 ; 
35.3) 
  
      
Body mass index < 21      
No 78 (96.3%) 20 (87.0%) 58 (100.0%) Reference  
Yes 3 (3.7%) 3 (13.0%) 0 (0.0%) 19.98 [0.63 – 635.32] 0.0208 
      
SEFI® score 7.7 ± 2.5 7.8 ± 2.8 7.6 ± 2.4 1.03 [0.85 – 1.26] 0.4560 
 (1.0 ; 5.1 ; 8.6 ; 
10.0 ; 10.0) 
(1.0 ; 5.0 ; 9.5 ; 
10.0 ; 10.0) 
(2.5 ; 5.1 ; 8.0 ; 10.0 ; 
10.0) 
  
      
SEFI® score < 7      
No 54 (66.7%) 15 (65.2%) 39 (67.2%) Reference  
Yes 27 (33.3%) 8 (34.8%) 19 (32.8%) 1.09 [0.40 – 3.03] 0.8617 
      
Mid-arm circumference 
(cm) 
29.4 ± 2.7 
(21.0 ; 27.5 ; 29.0 
; 31.0 ; 35.0) 
27.2 ± 2.0 
(21.0 ; 26.0 ; 27.0 
; 28.5 ; 31.0) 
30.3 ± 2.4 
(24.5 ; 29.0 ; 30.0 ; 32.0 ; 
35.0) 
0.50 [0.35 – 0.70] <0.0001 
      
TSF (mm) 7.1 ± 2.3 5.9 ± 2.0 7.6 ± 2.2 0.66 [0.51 – 0.87] 0.0017 
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Variable 
All patients 
(n=81) 
Low FFMI 
(n=23) 
Normal FFMI 
(n=58) 
Odds ratio [95% 
confidence interval] P value 
 (3.0 ; 5.0 ; 7.0 ; 
8.0 ; 14.0) 
(3.0 ; 4.0 ; 6.0 ; 
7.0 ; 10.0) 
(4.0 ; 6.0 ; 8.0 ; 9.0 ; 14.0)  
      
MAMC (mm) 271.5 ± 24.8 253.1 ± 21.4 278.8 ± 22.2 0.95 [0.92 – 0.97] <0.0001 
 (197.4 ; 256.2 ; 
270.6 ; 292.3 ; 
328.0) 
(197.4 ; 238.6 ; 
249.3 ; 269.3 ; 
300.6) 
(226.2 ; 264.9 ; 279.6 ; 
294.3 ; 328.0) 
  
      
Bioimpedance analysis      
      
Resistance 50 kHz 510.3 ± 89.6 597.7 ± 99.9 475.7 ± 55.8 1.03 [1.01 – 1.04] <0.0001 
 (380.0 ; 452.0 ; 
493.0 ; 542.0 ; 
937.0) 
(484.0 ; 539.0 ; 
572.0 ; 635.0 ; 
937.0) 
(380.0 ; 446.0 ; 468.0 ; 
502.0 ; 688.0) 
  
      
Reactance 50 kHz 44.2 ± 9.0 46.4 ± 6.7 43.3 ± 9.6 1.04 [0.98 – 1.10] 0.1632 
 (20.0 ; 39.0 ; 44.4 
; 50.6 ; 79.0) 
(33.8 ; 40.8 ; 46.2 
; 52.0 ; 57.4) 
(20.0 ; 37.5 ; 43.3 ; 50.0 ; 
79.0) 
  
      
50 kHz phase angle 5.0 ± 1.0 4.5 ± 0.8 5.2 ± 1.0 0.41 [0.22 – 0.76] 0.0033 
 (2.8 ; 4.3 ; 5.0 ; 
5.6 ; 8.9) 
(3.2 ; 3.9 ; 4.7 ; 
5.1 ; 5.7) 
(2.8 ; 4.4 ; 5.3 ; 5.8 ; 8.9)   
      
Fat-free mass (%) 68.5 ± 6.4 64.1 ± 7.8 70.3 ± 4.7 0.84 [0.77 – 0.93] 0.0019 
 (49.4 ; 66.2 ; 69.6 
; 72.7 ; 81.6) 
(49.4 ; 55.7 ; 67.3 
; 70.5 ; 74.1) 
(59.8 ; 67.3 ; 69.9 ; 73.3 ; 
81.6) 
  
      
Fat-free mass (kg) 50.7 ± 9.9 39.2 ± 7.4 55.2 ± 6.5 0.70 [0.59 – 0.83] <0.0001 
 (21.1 ; 45.0 ; 52.3 
; 57.8 ; 66.5) 
(21.1 ; 33.0 ; 41.3 
; 45.2 ; 50.0) 
(36.7 ; 51.5 ; 54.5 ; 60.1 ; 
66.5) 
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Variable 
All patients 
(n=81) 
Low FFMI 
(n=23) 
Normal FFMI 
(n=58) 
Odds ratio [95% 
confidence interval] P value 
      
Fat (%) 31.5 ± 6.4 35.9 ± 7.8 29.7 ± 4.7 1.19 [1.08 – 1.31] 0.0013 
 (18.4 ; 27.3 ; 30.4 
; 33.8 ; 50.6) 
(25.9 ; 29.5 ; 32.7 
; 44.3 ; 50.6) 
(18.4 ; 26.7 ; 30.1 ; 32.7 ; 
40.2) 
  
      
Fat mass (kg) 22.8 ± 4.6 21.5 ± 4.3 23.4 ± 4.7 0.91 [0.81 – 1.02] 0.0909 
 (14.2 ; 19.4 ; 23.1 
; 26.5 ; 34.2) 
(14.9 ; 18.4 ; 21.2 
; 23.8 ; 31.4) 
(14.2 ; 19.9 ; 23.7 ; 26.6 ; 
34.2) 
  
      
Fat mass index 8.3 ± 2.0 8.3 ± 2.2 8.3 ± 1.9 1.00 [0.79 – 1.28] 0.9708 
 (4.3 ; 7.0 ; 8.1 ; 
9.6 ; 13.8) 
(5.2 ; 6.9 ; 7.6 ; 
9.8 ; 13.8) 
(4.3 ; 7.0 ; 8.3 ; 9.6 ; 13.7)  
      
Total body water (%) 55.7 ± 4.9 55.9 ± 6.0 55.6 ± 4.4 1.01 [0.92 – 1.12] 0.8033 
 (45.2 ; 51.8 ; 55.6 
; 58.8 ; 66.7) 
(45.2 ; 51.6 ; 56.1 
; 59.4 ; 66.7) 
(47.1 ; 51.8 ; 55.3 ; 58.6 ; 
65.9) 
  
      
Extracellular water (%) 24.3 ± 2.1 24.9 ± 1.8 24.0 ± 2.2 1.24 [0.97 – 1.57] 0.0706 
 (20.3 ; 23.0 ; 24.1 
; 25.2 ; 33.2) 
(22.0 ; 23.6 ; 24.7 
; 26.3 ; 28.4) 
(20.3 ; 22.5 ; 23.7 ; 25.0 ; 
33.2) 
  
      
Intracellular water (%) 30.7 ± 3.0 30.2 ± 4.1 30.9 ± 2.5 0.93 [0.79 – 1.08] 0.4389 
 (18.6 ; 29.5 ; 31.3 
; 32.7 ; 36.1) 
(23.9 ; 25.9 ; 31.4 
; 33.5 ; 35.9) 
(18.6 ; 29.7 ; 31.2 ; 32.7 ; 
36.1) 
  
      
Body cell mass (kg) 32.3 ± 5.5 26.3 ± 4.8 34.7 ± 3.7 0.63 [0.51 – 0.78] <0.0001 
 (14.8 ; 29.9 ; 33.6 
; 36.1 ; 41.8) 
(14.8 ; 21.2 ; 28.7 
; 30.1 ; 32.2) 
(19.9 ; 33.1 ; 34.9 ; 37.1 ; 
41.8) 
  
      
Biological parameters      
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Variable 
All patients 
(n=81) 
Low FFMI 
(n=23) 
Normal FFMI 
(n=58) 
Odds ratio [95% 
confidence interval] P value 
      
Serum albumin 41.9 ± 3.0 41.8 ± 3.1 42.0 ± 3.0 0.98 [0.84 – 1.15] 0.8099 
 (35.8 ; 39.9 ; 42.3 
; 43.9 ; 47.6) 
(35.8 ; 40.2 ; 42.4 
; 44.3 ; 46.5) 
(35.9 ; 39.8 ; 42.3 ; 43.8 ; 
47.6) 
  
      
Serum transthyretin 0.3 ± 0.1 0.3 ± 0.1 0.3 ± 0.1 1.02 [0.40 – 2.61] 0.9749 
 (0.1 ; 0.2 ; 0.2 ; 
0.3 ; 0.4) 
(0.1 ; 0.2 ; 0.2 ; 
0.3 ; 0.4) 
(0.1 ; 0.2 ; 0.3 ; 0.3 ; 0.4)   
      
C reactive protein 8.2 ± 12.1 7.1 ± 10.1 8.6 ± 12.8 0.99 [0.95 – 1.03] 0.3563 
 (1.0 ; 1.7 ; 3.6 ; 
8.7 ; 61.6) 
(1.0 ; 1.5 ; 2.5 ; 
8.8 ; 38.7) 
(1.0 ; 1.8 ; 4.4 ; 8.7 ; 61.6)  
  
Qualitative variables: number (%). Quantitative variables: mean ± standard deviation (min; Q1; median ; Q3; max). FFMI, fat-free mass index ; 8 
MAMC, mid-arm muscular circumference; SEFI®, Simplified Evaluation of Food Intake®; TSF, triceps skinfold thickness. Missing data: serum 9 
transthyretin, n=3. 10 
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Table 3– Logistic regression multivariable analysis of factors associated with 
malnutrition, defined by low fat-free mass index (n = 81). The Odds ratio for continuous 
variables (body mass index) is given for 1-point increases. 
Variables 
Odds Ratio [95% 
confidence interval] P value 
Body mass index 0.26 [0.12 – 0.54] 0.0003 
Male gender 0.02 [0.00 – 0.33] 0.0055 
Tobacco use 0.10 [0.01 – 0.75] 0.0243 
 
Fat-free mass index was calculated as: fat-free mass (kg)/(height (m)
2
; below 17 was 
considered to be low or impaired for men and below 15 for women, as for COPD patients (8, 
20). 
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Table 4- Value of body mass index (BMI) and mid-arm circumference (MAC) for 
predicting low fat-free mass index (FFMI) in idiopathic pulmonary fibrosis (IPF) 
patients (n=81). 
 
 
 
 
 
 
 
Fat-free mass index (FFMI) was determined by bioimpedance analysis, calculated as: fat-free 
mass (kg)/(height (m)
2
, and  considered to be low or impaired (< 17 in men) and (<15 in 
women) as for COPD patients (8, 20). Sensitivity was 100 % for a BMI < 25 and/or CMB < 
30, (23/23; 95 % confidence interval (CI) 88-100%), while specificity was 57 % (33/58; 95 % 
CI 43–70 %), positive predictive value was 48 % (23/48; 95 % CI 33–63 %) and the negative 
predictive value was 100 % (33/33; 95 % CI 91–100 %). The BMI and MAC cutoffs 
associated with low FFMI were assessed by the Youden method. 
Variable Low FFMI Normal FFMI Patients (n) 
BMI < 25 and/or MAC < 30 23 25 48 
BMI ≥ 25 and MAC ≥ 30 0 33 33 
Patients (n) 23 58 81 
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Figure legends 
 
Figure 1- Area under the receiver operating characteristic curve (AUC) assessing body 
mass index (BMI) prediction of a low fat-free mass index (FFMI) (n=81). FFMI was 
determined by bioelectrical impedance analysis, and calculated as: fat-free mass (kg)/(height 
(m)
2
. FFMI was considered low when it was <17 in men or <15 in women (8, 20). A low BMI 
was associated with a lower fat-free mass index. AUC=0.91 [95% confidence interval (CI), 
0.84‒0.97]. The sensitivity, specificity, positive and negative predictive values for a BMI 
<25.4 were: 96%, 22/23, [95% CI, 78–100], 79%, 46/58, [67–89], 65%, 22/34, [47–80], and 
98%, 46/47, [89–100]. The BMI cut-off associated with low FFMI was assessed by the 
Youden method. 
 
Figure 2- Area under the receiver operating characteristic curve (AUC) assessing mid-
arm circumference (MAC) predictions of a low fat-free mass index (FFMI) (n=81). FFMI 
was determined by bioelectrical impedance analysis (fat-free mass (kg)/(height (m)
2
). FFMI 
was considered to be low if it was <17 in men or <15 in women (8, 20). A low MAC was 
associated with a low fat-free mass index. AUC=0.85 [95% confidence interval (CI), 0.76‒
0.94]. The sensitivity, specificity, positive and negative predictive values of a MAC <295 mm 
were: 91%, 21/23, [95% CI, 72–99], 66%, 38/58, [52–78], 51%, 21/41, [35–67], and 95%, 
38/40, [83–99]. The MAC cut-off associated with a low FFMI was assessed by the Youden 
method. 
  
ACCEPTED MANUSCRIPT
AC
CE
PT
ED
 M
AN
US
CR
IP
T
30 
 
Figure 1 
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Figure 2 
 
 
